{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:51:44Z","timestamp":1783129904146,"version":"3.54.6"},"publisher-location":"New York, NY","reference-count":98,"publisher":"Springer US","isbn-type":[{"value":"9781071647295","type":"print"},{"value":"9781071647301","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4730-1_1","type":"book-chapter","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T12:59:55Z","timestamp":1753707595000},"page":"3-21","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Progress and Future Directions in Exon Skipping and Inclusion Therapies: The Landscape of Oligonucleotide-Based Genetic Medicine"],"prefix":"10.1007","author":[{"given":"Saeed","family":"Anwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"1_CR1","first-page":"1","volume-title":"Clinical trials of genetic therapy with antisense DNA and DNA vectors","author":"JW Hawkins","year":"2020","unstructured":"Hawkins JW (2020) A brief history of genetic therapy: gene therapy, antisense technology, and genomics. In: Clinical trials of genetic therapy with antisense DNA and DNA vectors, 1st edn. CRC Press, Boca Raton, pp 1\u201338","edition":"1"},{"key":"1_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","volume":"525","author":"T Wirth","year":"2013","unstructured":"Wirth T, Parker N, Yl\u00e4-Herttuala S (2013) History of gene therapy. Gene 525:162\u2013169. https:\/\/doi.org\/10.1016\/j.gene.2013.03.137","journal-title":"Gene"},{"key":"1_CR3","doi-asserted-by":"publisher","unstructured":"Goswami R, Subramanian G, Silayeva L, Newkirk I, Doctor D, Chawla K, Chattopadhyay S, Chandra D, Chilukuri N, Betapudi V (2019) Gene therapy leaves a vicious cycle. Front Oncol 9. https:\/\/doi.org\/10.3389\/fonc.2019.00297","DOI":"10.3389\/fonc.2019.00297"},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1039\/D0CS01430C","volume":"50","author":"LK McKenzie","year":"2021","unstructured":"McKenzie LK, El-Khoury R, Thorpe JD, Damha MJ, Hollenstein M (2021) Recent progress in non-native nucleic acid modifications. Chem Soc Rev 50:5126\u20135164. https:\/\/doi.org\/10.1039\/D0CS01430C","journal-title":"Chem Soc Rev"},{"key":"1_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-1-0716-2010-6_2","volume-title":"Antisense RNA design, delivery, and analysis","author":"V Arechavala-Gomeza","year":"2022","unstructured":"Arechavala-Gomeza V, Garanto A (2022) Antisense RNA therapeutics: a brief overview. In: Antisense RNA design, delivery, and analysis, pp 33\u201349"},{"key":"1_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"JJA Lee","year":"2013","unstructured":"Lee JJA, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3:144\u2013176. https:\/\/doi.org\/10.3390\/jpm3030144","journal-title":"J Pers Med"},{"key":"1_CR7","doi-asserted-by":"publisher","first-page":"6975","DOI":"10.1021\/acs.jmedchem.2c00024","volume":"65","author":"JM Sasso","year":"2022","unstructured":"Sasso JM, Ambrose BJB, Tenchov R, Datta RS, Basel MT, DeLong RK, Zhou QA (2022) The progress and promise of RNA medicine \u2013 an arsenal of targeted treatments. J Med Chem 65:6975\u20137015. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00024","journal-title":"J Med Chem"},{"key":"1_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova A, Watts JK (2017) The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol 35:238\u2013248. https:\/\/doi.org\/10.1038\/nbt.3765","journal-title":"Nat Biotechnol"},{"key":"1_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1021\/acs.joc.0c02291","volume":"86","author":"BI Andrews","year":"2021","unstructured":"Andrews BI, Antia FD, Brueggemeier SB, Diorazio LJ, Koenig SG, Kopach ME, Lee H, Olbrich M, Watson AL (2021) Sustainability challenges and opportunities in oligonucleotide manufacturing. J Org Chem 86:49\u201361. https:\/\/doi.org\/10.1021\/acs.joc.0c02291","journal-title":"J Org Chem"},{"key":"1_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/jimd.12251","volume":"44","author":"EC Kuijper","year":"2021","unstructured":"Kuijper EC, Bergsma AJ, Pijnappel WWMP, Aartsma-Rus A (2021) Opportunities and challenges for antisense oligonucleotide therapies. J Inherit Metab Dis 44:72\u201387. https:\/\/doi.org\/10.1002\/jimd.12251","journal-title":"J Inherit Metab Dis"},{"key":"1_CR11","doi-asserted-by":"publisher","first-page":"13993","DOI":"10.1021\/acsnano.1c05099","volume":"15","author":"JP Bost","year":"2021","unstructured":"Bost JP, Barriga H, Holme MN, Gallud A, Maugeri M, Gupta D, Lehto T, Valadi H, Esbj\u00f6rner EK, Stevens MM, El-Andaloussi S (2021) Delivery of oligonucleotide therapeutics: chemical modifications, lipid nanoparticles, and extracellular vesicles. ACS Nano 15:13993\u201314021. https:\/\/doi.org\/10.1021\/acsnano.1c05099","journal-title":"ACS Nano"},{"key":"1_CR12","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/pharmaceutics15041130","volume":"15","author":"S Anwar","year":"2023","unstructured":"Anwar S, Mir F, Yokota T (2023) Enhancing the effectiveness of oligonucleotide therapeutics using cell-penetrating peptide conjugation, chemical modification, and carrier-based delivery strategies. Pharmaceutics 15:1130. https:\/\/doi.org\/10.3390\/pharmaceutics15041130","journal-title":"Pharmaceutics"},{"key":"1_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/171737a0","volume":"171","author":"JD Watson","year":"1953","unstructured":"Watson JD, Crick FHC (1953) Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature 171:737\u2013738. https:\/\/doi.org\/10.1038\/171737a0","journal-title":"Nature"},{"key":"1_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1084\/jem.79.2.137","volume":"79","author":"OT Avery","year":"1944","unstructured":"Avery OT, MacLeod CM, McCarty M (1944) Studies on the chemical nature of the substance inducing transformation of pneumococcal types. J Exp Med 79:137\u2013158. https:\/\/doi.org\/10.1084\/jem.79.2.137","journal-title":"J Exp Med"},{"key":"1_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.18388\/abp.2020_5805","volume":"68","author":"J Dulak","year":"2021","unstructured":"Dulak J (2021) Gene therapy. The legacy of Wac\u0142aw Szybalski*. Acta Biochim Pol 68:359\u2013375. https:\/\/doi.org\/10.18388\/abp.2020_5805","journal-title":"Acta Biochim Pol"},{"key":"1_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1073\/pnas.75.1.280","volume":"75","author":"PC Zamecnik","year":"1978","unstructured":"Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75:280\u2013284. https:\/\/doi.org\/10.1073\/pnas.75.1.280","journal-title":"Proc Natl Acad Sci USA"},{"key":"1_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0022-2836(69)90418-5","volume":"46","author":"AM Bobst","year":"1969","unstructured":"Bobst AM, Rottman F, Cerutti PA (1969) Effect of the methylation of the 2\u2032-hydroxyl groups in polyadenylic acid on its structure in weakly acidic and neutral solutions and on its capability to form ordered complexes with polyuridylic acid. J Mol Biol 46:221\u2013234. https:\/\/doi.org\/10.1016\/0022-2836(69)90418-5","journal-title":"J Mol Biol"},{"key":"1_CR18","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1021\/ja00970a054","volume":"88","author":"F Eckstein","year":"1966","unstructured":"Eckstein F (1966) Nucleoside Phosphorothioates. J Am Chem Soc 88:4292\u20134294. https:\/\/doi.org\/10.1021\/ja00970a054","journal-title":"J Am Chem Soc"},{"key":"1_CR19","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1021\/jo01026a009","volume":"29","author":"JF Codington","year":"1964","unstructured":"Codington JF, Doerr IL, Fox JJ (1964) Nucleosides. XVIII. Synthesis of 2\u2019-Fluorothymidine, 2\u2019-Fluorodeoxyuridine, and other 2\u2019-Halogeno-2\u2019-deoxy nucleosides1,2. J Org Chem 29:558\u2013564. https:\/\/doi.org\/10.1021\/jo01026a009","journal-title":"J Org Chem"},{"key":"1_CR20","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1021\/jo01026a008","volume":"29","author":"EJ Reist","year":"1964","unstructured":"Reist EJ, Benitez A, Goodman L (1964) The synthesis of some 5\u2019-Thiopentofuranosylpyrimidines1. J Org Chem 29:554\u2013558. https:\/\/doi.org\/10.1021\/jo01026a008","journal-title":"J Org Chem"},{"key":"1_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/nat.2014.0506","volume":"24","author":"F Eckstein","year":"2014","unstructured":"Eckstein F (2014) Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther 24:374\u2013387. https:\/\/doi.org\/10.1089\/nat.2014.0506","journal-title":"Nucleic Acid Ther"},{"key":"1_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/nat.2013.0454","volume":"24","author":"P J\u00e4rver","year":"2014","unstructured":"J\u00e4rver P, O\u2019Donovan L, Gait MJ (2014) A chemical view of oligonucleotides for exon skipping and related drug applications. Nucleic Acid Ther 24:37\u201347. https:\/\/doi.org\/10.1089\/nat.2013.0454","journal-title":"Nucleic Acid Ther"},{"key":"1_CR23","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1073\/pnas.48.12.2026","volume":"48","author":"EH Szybalska","year":"1962","unstructured":"Szybalska EH, Szybalski W (1962) DNA-mediated heritable transformation of a biochemical trait. Proc Natl Acad Sci USA 48:2026\u20132034","journal-title":"Proc Natl Acad Sci USA"},{"key":"1_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0022-2836(72)90151-9","volume":"72","author":"A Kumar","year":"1972","unstructured":"Kumar A, Khorana HG (1972) CVIII. Total synthesis of the structural gene for an alanine transfer ribonucleic acid from yeast. synthesis of an undecadeoxynucleotide, a decadeoxynucleotide and an octadeoxynucleotide corresponding to the nucleotide sequences 7 to 27. J Mol Biol 72:329\u2013349. https:\/\/doi.org\/10.1016\/0022-2836(72)90151-9","journal-title":"J Mol Biol"},{"key":"1_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0022-2836(78)90032-3","volume":"122","author":"J Summerton","year":"1978","unstructured":"Summerton J, Bartlett PA (1978) Sequence-specific crosslinking agents for nucleic acids. J Mol Biol 122:145\u2013162. https:\/\/doi.org\/10.1016\/0022-2836(78)90032-3","journal-title":"J Mol Biol"},{"key":"1_CR26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.175.4025.949","volume":"175","author":"T Friedmann","year":"1972","unstructured":"Friedmann T, Roblin R (1972) Gene therapy for human genetic disease? Science 175:949\u2013955. https:\/\/doi.org\/10.1126\/science.175.4025.949","journal-title":"Science"},{"key":"1_CR27","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/274923a0","volume":"274","author":"GJ Dimitriadis","year":"1978","unstructured":"Dimitriadis GJ (1978) Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes. Nature 274:923\u2013924. https:\/\/doi.org\/10.1038\/274923a0","journal-title":"Nature"},{"key":"1_CR28","first-page":"15","volume":"3","author":"AM Kreig","year":"2001","unstructured":"Kreig AM, Davis HL (2001) Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 3:15\u201324","journal-title":"Curr Opin Mol Ther"},{"key":"1_CR29","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1021\/ja00401a041","volume":"103","author":"MD Matteucci","year":"1981","unstructured":"Matteucci MD, Caruthers MH (1981) Synthesis of Deoxyoligonucleotides on a polymer support. J Am Chem Soc 103:3185\u20133191. https:\/\/doi.org\/10.1021\/ja00401a041","journal-title":"J Am Chem Soc"},{"key":"1_CR30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0040-4039(00)81376-3","volume":"24","author":"LJ McBride","year":"1983","unstructured":"McBride LJ, Caruthers MH (1983) Nucleotide chemistry. X. An investigation of several deoxynucleoside phosphoramidites useful for synthesizing deoxyoligonucleotides. Tetrahedron Lett 24:245\u2013248","journal-title":"Tetrahedron Lett"},{"key":"1_CR31","doi-asserted-by":"publisher","first-page":"5764","DOI":"10.1073\/pnas.85.16.5764","volume":"85","author":"KK Ogilvie","year":"1988","unstructured":"Ogilvie KK, Usman N, Nicoghosian K, Cedergren RJ (1988) Total chemical synthesis of a 77-nucleotide-long RNA sequence having methionine-acceptance activity. Proc Natl Acad Sci 85:5764\u20135768","journal-title":"Proc Natl Acad Sci"},{"key":"1_CR32","doi-asserted-by":"publisher","first-page":"7741","DOI":"10.1021\/ja00465a073","volume":"99","author":"KK Ogilvie","year":"1977","unstructured":"Ogilvie KK, Theriault N, Sadana KL (1977) Synthesis of Oligoribonucleotides. J Am Chem Soc 99:7741\u20137743. https:\/\/doi.org\/10.1021\/ja00465a073","journal-title":"J Am Chem Soc"},{"key":"1_CR33","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1021\/ja00332a054","volume":"106","author":"WJ Stec","year":"1984","unstructured":"Stec WJ, Zon G, Egan W, Stec B (1984) Automated solid-phase synthesis, separation, and stereochemistry of Phosphorothioate analogues of Oligodeoxyribonucleotides. J Am Chem Soc 106:6077\u20136079. https:\/\/doi.org\/10.1021\/ja00332a054","journal-title":"J Am Chem Soc"},{"key":"1_CR34","first-page":"71","volume-title":"Discoveries in antisense nucleic acids (advances in applied biotechnology series)","author":"J Summerton","year":"1989","unstructured":"Summerton J (1989) Uncharged nucleic acid analogs for therapeutic and diagnostic applications: oligomers assembled from ribose-derived subunits. In: Brakel C (ed) Discoveries in antisense nucleic acids (advances in applied biotechnology series). Portfolio Publishing Company, The Woodlands, pp 71\u201380"},{"key":"1_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6817-6_1","volume":"1565","author":"JE Summerton","year":"2017","unstructured":"Summerton JE (2017) Invention and early history of morpholinos: from pipe dream to practical products. Methods Mol Biol 1565:1\u201315. https:\/\/doi.org\/10.1007\/978-1-4939-6817-6_1","journal-title":"Methods Mol Biol"},{"key":"1_CR36","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1073\/pnas.86.16.6077","volume":"86","author":"RW Malone","year":"1989","unstructured":"Malone RW, Felgner PL, Verma IM (1989) Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci 86:6077\u20136081. https:\/\/doi.org\/10.1073\/pnas.86.16.6077","journal-title":"Proc Natl Acad Sci"},{"key":"1_CR37","doi-asserted-by":"publisher","first-page":"7413","DOI":"10.1073\/pnas.84.21.7413","volume":"84","author":"PL Felgner","year":"1987","unstructured":"Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci 84:7413\u20137417. https:\/\/doi.org\/10.1073\/pnas.84.21.7413","journal-title":"Proc Natl Acad Sci"},{"key":"1_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.braindev.2015.05.014","volume":"38","author":"M Matsuo","year":"2016","unstructured":"Matsuo M, Takeshima Y, Nishio H (2016) Contributions of Japanese patients to development of antisense therapy for DMD. Brain Dev 38:4\u20139. https:\/\/doi.org\/10.1016\/j.braindev.2015.05.014","journal-title":"Brain Dev"},{"key":"1_CR39","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/0006-291X(90)92185-3","volume":"170","author":"M Matsuo","year":"1990","unstructured":"Matsuo M, Masumura T, Nakajima T, Kitoh Y, Takumi T, Nishio H, Koga J, Nakamura H (1990) A very small frame-shifting deletion within exon 19 of the Duchenne muscular dystrophy gene. Biochem Biophys Res Commun 170:963\u2013967. https:\/\/doi.org\/10.1016\/0006-291X(90)92185-3","journal-title":"Biochem Biophys Res Commun"},{"key":"1_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2:90\u201395. https:\/\/doi.org\/10.1016\/0888-7543(88)90113-9","journal-title":"Genomics"},{"key":"1_CR41","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1172\/jci117693","volume":"95","author":"Y Takeshima","year":"1995","unstructured":"Takeshima Y, Nishio H, Sakamoto H, Nakamura H, Matsuo M (1995) Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J Clin Invest 95:515\u2013520. https:\/\/doi.org\/10.1172\/jci117693","journal-title":"J Clin Invest"},{"key":"1_CR42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1006\/bbrc.1996.1375","volume":"226","author":"ZAD Pramono","year":"1996","unstructured":"Pramono ZAD, Takeshima Y, Alimsardjono H, Ishii A, Takeda S et al (1996) Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun 226:445\u2013449. https:\/\/doi.org\/10.1006\/bbrc.1996.1375","journal-title":"Biochem Biophys Res Commun"},{"key":"1_CR43","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0387-7604(01)00326-6","volume":"23","author":"Y Takeshima","year":"2001","unstructured":"Takeshima Y, Wada H, Yagi M, Ishikawa Y, Ishikawa Y, Minami R, Nakamura H, Matsuo M (2001) Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain Dev 23:788\u2013790. https:\/\/doi.org\/10.1016\/S0387-7604(01)00326-6","journal-title":"Brain Dev"},{"key":"1_CR44","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1203\/01.pdr.0000215047.51278.7c","volume":"59","author":"Y Takeshima","year":"2006","unstructured":"Takeshima Y, Yagi M, Wada H, Ishibashi K, Nishiyama A, Kakumoto M, Sakaeda T, Saura R, Okumura K, Matsuo M (2006) Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res 59:690\u2013694","journal-title":"Pediatr Res"},{"key":"1_CR45","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/mcb.26.4.1333-1346.2006","volume":"26","author":"NK Singh","year":"2006","unstructured":"Singh NK, Singh NN, Androphy EJ, Singh RN (2006) Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 26:1333\u20131346. https:\/\/doi.org\/10.1128\/mcb.26.4.1333-1346.2006","journal-title":"Mol Cell Biol"},{"key":"1_CR46","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4161\/rna.6.3.8723","volume":"6","author":"NN Singh","year":"2009","unstructured":"Singh NN, Shishimorova M, Lu CC, Gangwani L, Singh RN (2009) A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol 6:341\u2013350. https:\/\/doi.org\/10.4161\/rna.6.3.8723","journal-title":"RNA Biol"},{"key":"1_CR47","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/gt.2017.34","volume":"24","author":"NN Singh","year":"2017","unstructured":"Singh NN, Howell MD, Androphy EJ, Singh RN (2017) How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther 24:520\u2013526. https:\/\/doi.org\/10.1038\/gt.2017.34","journal-title":"Gene Ther"},{"key":"1_CR48","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96:6307\u20136311. https:\/\/doi.org\/10.1073\/pnas.96.11.6307","journal-title":"Proc Natl Acad Sci USA"},{"key":"1_CR49","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","volume":"8","author":"UR Monani","year":"1999","unstructured":"Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AHM, McPherson JD (1999) A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 8:1177\u20131183. https:\/\/doi.org\/10.1093\/hmg\/8.7.1177","journal-title":"Hum Mol Genet"},{"key":"1_CR50","doi-asserted-by":"publisher","unstructured":"Iglesias-Lopez C, Agust\u00ed A, Obach M, Vallano A (2019) Regulatory framework for advanced therapy medicinal products in Europe and United States. Front Pharmacol 10. https:\/\/doi.org\/10.3389\/fphar.2019.00921","DOI":"10.3389\/fphar.2019.00921"},{"key":"1_CR51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.33892\/aph.2022.92.38-44","volume":"92","author":"M Bege","year":"2022","unstructured":"Bege M, Borb\u00e1s A (2022) Rise and fall of fomivirsen, the first approved gene silencing medicine: a historical review. Acta Pharm Hung 92:38\u201344. https:\/\/doi.org\/10.33892\/aph.2022.92.38-44","journal-title":"Acta Pharm Hung"},{"key":"1_CR52","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1076\/ocii.7.3.189.4007","volume":"7","author":"MD de Smet","year":"1999","unstructured":"de Smet MD, Meenken C, Van Den Horn GJ (1999) Fomivirsen \u2013 a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm 7:189\u2013198. https:\/\/doi.org\/10.1076\/ocii.7.3.189.4007","journal-title":"Ocul Immunol Inflamm"},{"key":"1_CR53","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806\u2013811. https:\/\/doi.org\/10.1038\/35888","journal-title":"Nature"},{"key":"1_CR54","first-page":"1612","volume":"164","author":"B Sibbald","year":"2001","unstructured":"Sibbald B (2001) Death but one unintended consequence of gene-therapy trial. Can Med Assoc J 164:1612","journal-title":"Can Med Assoc J"},{"key":"1_CR55","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","volume":"25","author":"CA Stein","year":"2017","unstructured":"Stein CA, Castanotto D (2017) FDA-approved oligonucleotide therapies in 2017. Mol Ther 25:1069\u20131075. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.023","journal-title":"Mol Ther"},{"key":"1_CR56","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KR Lim","year":"2017","unstructured":"Lim KR, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545. https:\/\/doi.org\/10.2147\/DDDT.S97635","journal-title":"Drug Des Devel Ther"},{"key":"1_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-1-4939-8651-4_4","volume-title":"Exon skipping and inclusion therapies: methods and protocols","author":"K Goodkey","year":"2018","unstructured":"Goodkey K, Aslesh T, Maruyama R, Yokota T (2018) Nusinersen in the treatment of spinal muscular atrophy. In: Exon skipping and inclusion therapies: methods and protocols, pp 69\u201376"},{"key":"1_CR58","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00003495-199957030-00010","volume":"57","author":"CM Perry","year":"1999","unstructured":"Perry CM, Barman Balfour JA (1999) Fomivirsen. Drugs 57:375\u2013380. https:\/\/doi.org\/10.2165\/00003495-199957030-00010","journal-title":"Drugs"},{"key":"1_CR59","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1358\/dot.2021.57.12.3352740","volume":"57","author":"H Wilton-Clark","year":"2021","unstructured":"Wilton-Clark H, Yokota T (2021) Casimersen for Duchenne muscular dystrophy. Drugs Today 57:707. https:\/\/doi.org\/10.1358\/dot.2021.57.12.3352740","journal-title":"Drugs Today"},{"key":"1_CR60","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40265-021-01511-3","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY (2021) Givosiran: a review in acute hepatic porphyria. Drugs 81:841\u2013848. https:\/\/doi.org\/10.1007\/s40265-021-01511-3","journal-title":"Drugs"},{"key":"1_CR61","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ (2022) Vutrisiran: first approval. Drugs 82:1419\u20131425. https:\/\/doi.org\/10.1007\/s40265-022-01765-5","journal-title":"Drugs"},{"key":"1_CR62","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN (2021) Inclisiran: first approval. Drugs 81:389\u2013395. https:\/\/doi.org\/10.1007\/s40265-021-01473-6","journal-title":"Drugs"},{"key":"1_CR63","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair HA (2023) Tofersen: first approval. Drugs 83:1039\u20131043. https:\/\/doi.org\/10.1007\/s40265-023-01904-6","journal-title":"Drugs"},{"key":"1_CR64","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd1955","volume":"5","author":"EWM Ng","year":"2006","unstructured":"Ng EWM, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123\u2013132. https:\/\/doi.org\/10.1038\/nrd1955","journal-title":"Nat Rev Drug Discov"},{"key":"1_CR65","doi-asserted-by":"publisher","unstructured":"Hair P, Cameron F, McKeage K (2013) Mipomersen sodium: first global approval. Drugs 73. https:\/\/doi.org\/10.1007\/s40265-013-0042-2","DOI":"10.1007\/s40265-013-0042-2"},{"key":"1_CR66","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1310\/hpj5110-847","volume":"51","author":"DE Baker","year":"2016","unstructured":"Baker DE, Demaris K (2016) Defibrotide. Hosp Pharm 51:847\u2013854. https:\/\/doi.org\/10.1310\/hpj5110-847","journal-title":"Hosp Pharm"},{"key":"1_CR67","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM (2017) Nusinersen: first global approval. Drugs 77:473\u2013479. https:\/\/doi.org\/10.1007\/s40265-017-0711-7","journal-title":"Drugs"},{"key":"1_CR68","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM (2018) Patisiran: first global approval. Drugs 78:1625\u20131631. https:\/\/doi.org\/10.1007\/s40265-018-0983-6","journal-title":"Drugs"},{"key":"1_CR69","doi-asserted-by":"publisher","unstructured":"Keam SJ (2018) Inotersen: first global approval. Drugs 78. https:\/\/doi.org\/10.1007\/s40265-018-0968-5","DOI":"10.1007\/s40265-018-0968-5"},{"key":"1_CR70","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","volume":"81","author":"LJ Scott","year":"2021","unstructured":"Scott LJ, Keam SJ (2021) Lumasiran: first approval. Drugs 81:277\u2013282. https:\/\/doi.org\/10.1007\/s40265-020-01463-0","journal-title":"Drugs"},{"key":"1_CR71","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2147\/DDDT.S281631","volume":"16","author":"CN Majeed","year":"2022","unstructured":"Majeed CN, Ma CD, Xiao T, Rudnick S, Bonkovsky HL (2022) Spotlight on Givosiran as a treatment option for adults with acute hepatic porphyria: design, development, and place in therapy. Drug Des Devel Ther 16:1827\u20131845. https:\/\/doi.org\/10.2147\/DDDT.S281631","journal-title":"Drug Des Devel Ther"},{"key":"1_CR72","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/0929867324666170718101946","volume":"25","author":"A Fernandez-Marmiesse","year":"2017","unstructured":"Fernandez-Marmiesse A, Gouveia S, Couce ML (2017) NGS technologies as a turning point in rare disease research, diagnosis and treatment. Curr Med Chem 25:404\u2013432. https:\/\/doi.org\/10.2174\/0929867324666170718101946","journal-title":"Curr Med Chem"},{"key":"1_CR73","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.tips.2018.09.001","volume":"39","author":"D Li","year":"2018","unstructured":"Li D, Mastaglia FL, Fletcher S, Wilton SD (2018) Precision medicine through antisense oligonucleotide-mediated exon skipping. Trends Pharmacol Sci 39:982\u2013994. https:\/\/doi.org\/10.1016\/j.tips.2018.09.001","journal-title":"Trends Pharmacol Sci"},{"key":"1_CR74","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrg3555","volume":"14","author":"KM Boycott","year":"2013","unstructured":"Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE (2013) Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet 14:681\u2013691. https:\/\/doi.org\/10.1038\/nrg3555","journal-title":"Nat Rev Genet"},{"key":"1_CR75","doi-asserted-by":"publisher","unstructured":"Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, Covello G, Denti MA, Desviat LR, Echevarr\u00eda L, Foged C, Gaina G, Garanto A, Goyenvalle AT, Guzowska M, Holodnuka I, Jones DR, Krause S, Lehto T, Montolio M, Van Roon-Mom W, Arechavala-Gomeza V (2021) Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med 13. https:\/\/doi.org\/10.15252\/emmm.202013243","DOI":"10.15252\/emmm.202013243"},{"key":"1_CR76","doi-asserted-by":"publisher","unstructured":"Kulkarni JA, Cullis PR, van der Meel R (2018) Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther 28. https:\/\/doi.org\/10.1089\/nat.2018.0721","DOI":"10.1089\/nat.2018.0721"},{"key":"1_CR77","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","volume":"23","author":"K Paunovska","year":"2022","unstructured":"Paunovska K, Loughrey D, Dahlman JE (2022) Drug delivery systems for RNA therapeutics. Nat Rev Genet 23:265\u2013280. https:\/\/doi.org\/10.1038\/s41576-021-00439-4","journal-title":"Nat Rev Genet"},{"key":"1_CR78","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1089\/nat.2021.0085","volume":"32","author":"DR Corey","year":"2022","unstructured":"Corey DR, Damha MJ, Manoharan M (2022) Challenges and opportunities for nucleic acid therapeutics. Nucleic Acid Ther 32:8\u201313. https:\/\/doi.org\/10.1089\/nat.2021.0085","journal-title":"Nucleic Acid Ther"},{"key":"1_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2015.02.003","volume":"203","author":"C Lorenzer","year":"2015","unstructured":"Lorenzer C, Dirin M, Winkler AM, Baumann V, Winkler J (2015) Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics. J Control Release 203:1\u201315. https:\/\/doi.org\/10.1016\/j.jconrel.2015.02.003","journal-title":"J Control Release"},{"key":"1_CR80","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrg3978","volume":"16","author":"A Wittrup","year":"2015","unstructured":"Wittrup A, Lieberman J (2015) Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet 16:543\u2013552. https:\/\/doi.org\/10.1038\/nrg3978","journal-title":"Nat Rev Genet"},{"key":"1_CR81","doi-asserted-by":"publisher","unstructured":"Wu SY, Lopez-Berestein G, Calin GA, Sood AK (2014) RNAi therapies: drugging the undruggable. Sci Transl Med 6. https:\/\/doi.org\/10.1126\/scitranslmed.3008362","DOI":"10.1126\/scitranslmed.3008362"},{"key":"1_CR82","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-pharmtox-010715-103633","volume":"56","author":"ML Bobbin","year":"2016","unstructured":"Bobbin ML, Rossi JJ (2016) RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol 56:103\u2013122. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010715-103633","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1_CR83","doi-asserted-by":"publisher","unstructured":"Markati T, De Waele L, Schara-Schmidt U, Servais L (2021) Lessons learned from discontinued clinical developments in Duchenne muscular dystrophy. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.735912","DOI":"10.3389\/fphar.2021.735912"},{"key":"1_CR84","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nrd.2016.226","volume":"15","author":"A Mullard","year":"2016","unstructured":"Mullard A (2016) RNAi hits another rut. Nat Rev Drug Discov 15:738\u2013738. https:\/\/doi.org\/10.1038\/nrd.2016.226","journal-title":"Nat Rev Drug Discov"},{"key":"1_CR85","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41587-022-01304-3","volume":"40","author":"J Maraganore","year":"2022","unstructured":"Maraganore J (2022) Reflections on Alnylam. Nat Biotechnol 40:641\u2013650. https:\/\/doi.org\/10.1038\/s41587-022-01304-3","journal-title":"Nat Biotechnol"},{"key":"1_CR86","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s43586-022-00100-2","volume":"2","author":"C Pizzamiglio","year":"2022","unstructured":"Pizzamiglio C, Vernon HJ, Hanna MG, Pitceathly RDS (2022) Designing clinical trials for rare diseases: unique challenges and opportunities. Nat Rev Methods Prim 2:13. https:\/\/doi.org\/10.1038\/s43586-022-00100-2","journal-title":"Nat Rev Methods Prim"},{"key":"1_CR87","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","volume":"56","author":"S Anwar","year":"2020","unstructured":"Anwar S, Yokota T (2020) Golodirsen for Duchenne muscular dystrophy. Drugs Today (Barc) 56:491\u2013504. https:\/\/doi.org\/10.1358\/dot.2020.56.8.3159186","journal-title":"Drugs Today (Barc)"},{"key":"1_CR88","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","volume":"55","author":"RR Roshmi","year":"2019","unstructured":"Roshmi RR, Yokota T (2019) Viltolarsen for the treatment of Duchenne muscular dystrophy. Drugs Today 55:627\u2013639. https:\/\/doi.org\/10.1358\/dot.2019.55.10.3045038","journal-title":"Drugs Today"},{"key":"1_CR89","doi-asserted-by":"publisher","unstructured":"Quemener AM, Bachelot L, Forestier A, Donnou-Fournet E, Gilot D, Galibert M (2020) The powerful world of antisense oligonucleotides: from bench to bedside. WIREs RNA 11. https:\/\/doi.org\/10.1002\/wrna.1594","DOI":"10.1002\/wrna.1594"},{"key":"1_CR90","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3390\/jcm9062004","volume":"9","author":"K Dhuri","year":"2020","unstructured":"Dhuri K, Bechtold C, Quijano E, Pham H, Gupta A, Vikram A, Bahal R (2020) Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med 9:2004. https:\/\/doi.org\/10.3390\/jcm9062004","journal-title":"J Clin Med"},{"key":"1_CR91","unstructured":"Coherent Market Insights (2022) Antisense oligonucleotides market analysis covering size, share, growth, trends and upcoming opportunities 2028. Seattle"},{"key":"1_CR92","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-0716-2772-3_2","volume-title":"Muscular dystrophy therapeutics","author":"RR Roshmi","year":"2023","unstructured":"Roshmi RR, Yokota T (2023) Viltolarsen: from preclinical studies to FDA approval. In: Muscular dystrophy therapeutics, pp 31\u201341"},{"key":"1_CR93","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13012-018-0784-z","volume":"13","author":"Y Bombard","year":"2018","unstructured":"Bombard Y, Baker GR, Orlando E, Fancott C, Bhatia P, Casalino S, Onate K, Denis J-L, Pomey M-P (2018) Engaging patients to improve quality of care: a systematic review. Implement Sci 13:98. https:\/\/doi.org\/10.1186\/s13012-018-0784-z","journal-title":"Implement Sci"},{"key":"1_CR94","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259\u2013293. https:\/\/doi.org\/10.1146\/annurev.pharmtox.010909.105654","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1_CR95","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","volume":"33","author":"JH Chan","year":"2006","unstructured":"Chan JH, Lim S, Wong WF (2006) Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 33:533\u2013540. https:\/\/doi.org\/10.1111\/j.1440-1681.2006.04403.x","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1_CR96","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","volume":"46","author":"X Shen","year":"2018","unstructured":"Shen X, Corey DR (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46:1584\u20131600. https:\/\/doi.org\/10.1093\/nar\/gkx1239","journal-title":"Nucleic Acids Res"},{"key":"1_CR97","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1016\/S0040-4039(98)01084-3","volume":"39","author":"S Obika","year":"1998","unstructured":"Obika S, Nanbu D, Hari Y, Andoh J, Morio K, Doi T, Imanishi T (1998) Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2\u2032-O,4\u2032-C-methyleneribonucleosides. Tetrahedron Lett 39:5401\u20135404. https:\/\/doi.org\/10.1016\/S0040-4039(98)01084-3","journal-title":"Tetrahedron Lett"},{"key":"1_CR98","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ddtec.2005.08.012","volume":"2","author":"S Kauppinen","year":"2005","unstructured":"Kauppinen S, Vester B, Wengel J (2005) Locked nucleic acid (LNA): high affinity targeting of RNA for diagnostics and therapeutics. Drug Discov Today Technol 2:287\u2013290. https:\/\/doi.org\/10.1016\/j.ddtec.2005.08.012","journal-title":"Drug Discov Today Technol"}],"container-title":["Methods in Molecular Biology","Exon Skipping and Inclusion Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4730-1_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:06:17Z","timestamp":1780747577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4730-1_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071647295","9781071647301"],"references-count":98,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4730-1_1","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"29 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}